moxin clarithromycin sustained release tablet 0

Description

Indication & Scope

MoXin® (clarithromycin sustained-release tablets) is a prescription macrolide antibiotic indicated for infections caused by clarithromycin-sensitive microorganisms, including lower respiratory tract infections, upper respiratory tract infections, and mild-to-moderate skin and soft-tissue infections.

Mechanism: Clarithromycin binds to the bacterial 50S ribosomal subunit and inhibits bacterial protein synthesis.
Drug class: Macrolide antibiotic.
Clinical use: Treatment of susceptible respiratory and mild-to-moderate skin and soft-tissue infections.

Specification

Generic Name	Clarithromycin Sustained-release Tablets
Brand Name	MoXin®
Ingredient	Clarithromycin
Dosage Form	Sustained-release tablet
Package	0.5 g/tablet, 7 tablets/box
Conditions Treated	Lower respiratory tract, upper respiratory tract, and mild-to-moderate skin and soft-tissue infections caused by clarithromycin-sensitive microorganisms.
Taboos	Hypersensitivity to clarithromycin or other macrolides; severe renal impairment with creatinine clearance <30 mL/min; concomitant use with astemizole, cisapride, pimozide, or terfenadine.
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store at room temperature in a dry place.
Manufacturer	Hainan Poly Pharm Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	H20051296
Approval Date	August 8, 2025
Shelf Life	24 months

How to use ?

Recommended Dose: Adults and patients aged ≥12 years: 500 mg once daily. For severe infections, 1,000 mg once daily.

Time: Usually 7–14 days.

Instructions for use: Take orally with food. Swallow the tablet whole; do not crush or chew. Patients under 12 years should use an appropriate non-sustained-release formulation.

Interaction: Clarithromycin inhibits CYP3A and may increase concentrations of CYP3A-metabolized drugs. Important interactions include certain statins, carbamazepine, calcium-channel blockers, warfarin, digoxin, and other medicines. Avoid concomitant use with astemizole, cisapride, pimozide, and terfenadine.

Side effects: Common adverse reactions include gastrointestinal symptoms, headache, dizziness, taste disturbance, and transient elevations in liver enzymes. Less common or serious reactions may include hypersensitivity, hepatotoxicity, pseudomembranous colitis, and cardiac QT prolongation or arrhythmias.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is MoXin® used for?

It is used to treat infections caused by clarithromycin-sensitive microorganisms, including respiratory and mild-to-moderate skin and soft-tissue infections.

How should MoXin® be taken?

It is usually taken as 500 mg once daily with food. The tablet must be swallowed whole and should not be crushed or chewed.

Can children use this medicine?

Patients aged 12 years and older may use the sustained-release formulation according to the adult regimen. Children under 12 years should use another appropriate formulation.

Can patients with kidney disease use it?

The sustained-release formulation is contraindicated in patients with creatinine clearance below 30 mL/min. Dose reduction is required for moderate renal impairment.